Login to Your Account



'Blockbuster' Stem Cell Therapy?

Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data

By Jennifer Boggs


Wednesday, April 28, 2010
Impressive, though early stage, Phase I data already has Pluristem Therapeutics Inc. setting the stage for Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription